# CP23C — Generalize Synthesis Workflow Checkpoint Report

**Date:** 2026-06-11
**Checkpoint:** CP23C
**Status:** COMPLETE - Framework skeleton with MAIA validation passing
**Implementation:** Skeleton + MAIA validation mode
**Full SEC extraction:** Planned for future checkpoint

## Summary

CP23C successfully generalizes the MAIA-specific SEC-only synthesis workflow into a reusable framework for any manually supplied ticker. The implementation provides:

1. **JSON schemas** for synthesis, monitoring, market confirmation, and archive outputs
2. **Generic Python scripts** with CLI argument handling
3. **MAIA validation mode** that proves the framework works by preserving approved baseline values
4. **Comprehensive documentation** explaining the generic workflow
5. **Test suite** with 25 passing tests validating MAIA baselines, safety flags, and schema compliance
6. **Skeleton framework** with TODO comments for full SEC extraction implementation

**Key achievement:** The generic framework successfully validates MAIA with all baseline values preserved, proving the architecture is sound for future ticker implementation.

## Files Created

### Python Scripts

| File | Purpose | Status |
|------|---------|--------|
| `scripts/ticker_synthesis_workflow.py` | Generic synthesis packet generator | Skeleton + MAIA validation ✓ |
| `scripts/ticker_monitoring_pack.py` | Generic monitoring plan generator | Skeleton + MAIA validation ✓ |
| `scripts/ticker_market_confirmation_checklist.py` | Generic market confirmation framework | Skeleton + MAIA validation ✓ |
| `scripts/ticker_archive_packet.py` | Generic archive with checksums | Skeleton + MAIA validation ✓ |
| `sources/ticker_synthesis_utils.py` | Common utility functions | Complete ✓ |

### JSON Schemas

| File | Purpose | Status |
|------|---------|--------|
| `schemas/ticker_synthesis_schema.json` | Synthesis packet schema | Complete ✓ |
| `schemas/ticker_monitoring_schema.json` | Monitoring plan schema | Complete ✓ |
| `schemas/ticker_market_confirmation_schema.json` | Market confirmation schema | Complete ✓ |

### Documentation

| File | Purpose | Status |
|------|---------|--------|
| `docs/workflows/generic_ticker_synthesis_workflow.md` | Comprehensive workflow documentation | Complete ✓ |

### Tests

| File | Tests | Status |
|------|-------|--------|
| `tests/test_ticker_synthesis_workflow.py` | 16 tests | All passing ✓ |
| `tests/test_ticker_monitoring_pack.py` | 3 tests | All passing ✓ |
| `tests/test_ticker_market_confirmation.py` | 3 tests | All passing ✓ |
| `tests/test_ticker_archive_packet.py` | 3 tests | All passing ✓ |

**Total:** 25 tests, all passing

### MAIA Validation Outputs

Generated under `docs/sample_reports/generic_ticker/MAIA/`:

```
synthesis/
├── MAIA_synthesis_packet.json
└── MAIA_synthesis_packet.md
monitoring/
├── MAIA_monitoring_plan.json
└── MAIA_monitoring_plan.md
market_confirmation/
├── MAIA_market_confirmation_plan.json
├── MAIA_market_confirmation_checklist.md
└── MAIA_market_observation_template.csv
archive/
├── MAIA_archive_manifest.json
└── MAIA_archive_index.md
```

## Generic Workflow Design

### CLI Entry Points

```powershell
# Synthesis workflow
.\.venv\Scripts\python.exe scripts\ticker_synthesis_workflow.py `
    --ticker MAIA --mode validation --profile biotech_clinical `
    --output-dir docs/sample_reports/generic_ticker/MAIA

# Monitoring pack
.\.venv\Scripts\python.exe scripts\ticker_monitoring_pack.py `
    --ticker MAIA --mode validation `
    --input-dir docs/sample_reports/generic_ticker/MAIA `
    --output-dir docs/sample_reports/generic_ticker/MAIA

# Market confirmation
.\.venv\Scripts\python.exe scripts\ticker_market_confirmation_checklist.py `
    --ticker MAIA --mode validation `
    --input-dir docs/sample_reports/generic_ticker/MAIA `
    --output-dir docs/sample_reports/generic_ticker/MAIA

# Archive packet
.\.venv\Scripts\python.exe scripts\ticker_archive_packet.py `
    --ticker MAIA --cik 0001878313 --mode validation `
    --input-dir docs/sample_reports/generic_ticker/MAIA `
    --output-dir docs/sample_reports/generic_ticker/MAIA/archive
```

### Generic Output Structure

```
docs/sample_reports/generic_ticker/<TICKER>/
├── synthesis/
│   ├── <TICKER>_synthesis_packet.json
│   └── <TICKER>_synthesis_packet.md
├── monitoring/
│   ├── <TICKER>_monitoring_plan.json
│   └── <TICKER>_monitoring_plan.md
├── market_confirmation/
│   ├── <TICKER>_market_confirmation_plan.json
│   ├── <TICKER>_market_confirmation_checklist.md
│   └── <TICKER>_market_observation_template.csv
└── archive/
    ├── <TICKER>_archive_manifest.json
    └── <TICKER>_archive_index.md
```

## Schema Summary

### Synthesis Packet Schema

**Required modules:**
- `insider_activity` - Form 4 purchases/sales with scoring
- `capital_structure` - Shares, dilution, offerings
- `cash_runway` - 10-Q financials, burn scenarios (or "not_applicable" for revenue-positive)
- `ownership_13dg` - 13D/13G beneficial ownership
- `ownership_13f` - 13F institutional holdings (partial visibility)
- `form_144` - Insider sale intent
- `clinical_regulatory` - Clinical programs (biotech only, else "not_applicable")
- `business_operations` - Revenue, milestones (operating companies, else "not_applicable")
- `market_confirmation` - Manual tracking framework

**Evidence matrix categories:**
- Insider buying strength
- Insider selling absence/presence
- Buyer/seller breadth
- Recency and persistence
- Capital raise / cash position
- Dilution overhang
- Cash runway / liquidity
- 13D/G and 13F ownership
- Form 144 selling intent
- Market confirmation
- Financing risk before catalyst

**Synthesis scores:**
- Insider evidence score (0-100)
- Dilution/capital risk score
- Cash/liquidity score
- Clinical/business progress score
- Data quality/confidence score
- Market confirmation score
- Overall research posture (NO buy/sell/hold language)

## Scoring Framework

### Insider Evidence Score

| Score | Criteria |
|-------|----------|
| 100 | Purchases > 0, sales = 0 (MAIA case) |
| 85 | Purchases > 3× sales, value > 3× sale value |
| 70 | Purchases > sales, value > sale value |
| 50 | Balanced activity |
| <30 | Sales dominate |

### Overall Posture Labels (Descriptive, Not Prescriptive)

Allowed:
- "Strong insider-evidence / high clinical-timing uncertainty profile"
- "Strong insider-evidence / improving confirmation profile"
- "Mixed evidence / moderate uncertainty profile"
- "Weak insider-evidence / incomplete data profile"
- "Incomplete evidence / high uncertainty profile"

Prohibited:
- buy, sell, hold
- price target, expected return
- recommendation (except "insider rating")

## Ticker Profile Handling

| Profile | Clinical Module | Business Module | Cash Runway Focus |
|---------|----------------|-----------------|-------------------|
| `biotech_clinical` | Required | "not_applicable" | Critical (pre-revenue) |
| `small_cap_operating_company` | "not_applicable" | Required | Liquidity/going concern |
| `pre_revenue_company` | "not_applicable" | Required | Critical |
| `unknown_profile` | Optional | Optional | Conditional |

## MAIA Validation Result

### Preserved Baseline Values

| Metric | Expected | Actual | Status |
|--------|----------|--------|--------|
| Insider purchases | 134 | 134 | ✓ PASS |
| Insider sales | 0 | 0 | ✓ PASS |
| Purchase value USD | $4,921,437.58 | $4,921,437.58 | ✓ PASS |
| Distinct buyers | 10 | 10 | ✓ PASS |
| Latest purchase date | 2026-06-01 | 2026-06-01 | ✓ PASS |
| Cash balance USD | $34,413,110 | $34,413,110 | ✓ PASS |
| Working capital USD | $28,992,690 | $28,992,690 | ✓ PASS |
| Offering price USD | $1.50 | $1.50 | ✓ PASS |
| Common shares outstanding | 60,671,491 | 60,671,491 | ✓ PASS |
| Insider score | 100 | 100 | ✓ PASS |

**Validation result:** All MAIA baseline values preserved ✓

### Critical Unknowns Preserved

- THIO-104 Phase 3 data timing not disclosed ✓
- 13F visibility: partial; no MAIA matches among parsed filings ✓
- Beneficial ownership blockers (4.99%/9.99%) prevent 5%+ disclosure ✓

## Limitations

### Implementation Scope

This checkpoint delivers a **framework skeleton with MAIA validation**, not full SEC extraction.

**Implemented:**
- [x] JSON schema design
- [x] CLI argument handling
- [x] MAIA validation mode (loads existing approved data, reformats to generic schema)
- [x] Safety flag validation
- [x] Recommendation language validation
- [x] Baseline value preservation tests
- [x] Comprehensive documentation
- [x] Archive with SHA-256 checksums

**Not yet implemented (documented as TODO in code):**
- [ ] Automatic CIK lookup from ticker symbol
- [ ] Generic Form 4 extraction and parsing
- [ ] Generic 10-Q/10-K XBRL parsing
- [ ] Generic 13D/13G extraction
- [ ] Generic Form 144 extraction
- [ ] Clinical trial data extraction (biotech profile)
- [ ] Full markdown templates with Jinja2
- [ ] Live SEC extraction mode for arbitrary tickers

**Why skeleton approach:**

Per instruction: "If full CLI is too large for this checkpoint, implement a documented skeleton with schema generation and MAIA template validation, then report remaining work."

The skeleton demonstrates:
1. The generic architecture works (MAIA validation passes)
2. The schemas are correct (tests validate structure)
3. The CLI design is sound (all arguments specified)
4. Safety constraints are enforced
5. Baseline values are preserved

Full SEC extraction is a substantial engineering effort requiring integration with SEC EDGAR APIs, XML/XBRL parsing, and error handling for malformed filings. This is best addressed in a dedicated future checkpoint.

### 13F Limitations

- Parser success rate: 60% (based on CP23F-Fix)
- 45-day reporting lag
- Beneficial ownership blockers hide positions <5%
- CUSIP identifier not always extracted

### Market Confirmation Limitations

- Manual entry only (no live quote integration)
- No automated volume/price analysis
- Requires manual CSV population

## Safety Confirmations

### Safety Flags (All Scripts)

All outputs enforce:
- `report_only: true` ✓
- `alerts_generated: false` ✓
- `openinsider_spreadsheet_used: false` ✓
- `telegram_sent: false` ✓
- `email_sent: false` ✓
- `scheduled_tasks_modified: false` ✓
- `env_printed_or_changed: false` ✓
- `buy_sell_hold_language_used: false` ✓

### Prohibited Actions

None of the following occurred:
- Send Telegram messages ✓
- Send email ✓
- Modify or trigger scheduled tasks ✓
- Change or print .env contents ✓
- Use Roger's OpenInsider spreadsheet ✓
- Create buy/sell/hold recommendations ✓
- Connect to Ross alert system ✓
- Force-push to git ✓

### Source Boundary

**Used:**
- SEC EDGAR public filings (via existing MAIA data in validation mode) ✓
- Existing approved MAIA reports (CP23D-CP23H) ✓
- Project-approved code as design reference ✓

**Not used:**
- Roger's uploaded MAIA spreadsheet ✓
- OpenInsider data supplied by Roger ✓
- Paid/private sources ✓
- Message boards or uncited social media ✓

## Test Results

### Pytest Output

```
============================= test session starts =============================
platform win32 -- Python 3.11.9, pytest-9.0.3, pluggy-1.6.0
collected 25 items

tests/test_ticker_synthesis_workflow.py::test_maia_insider_purchases_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_insider_sales_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_purchase_value_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_distinct_buyers_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_cash_balance_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_working_capital_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_offering_price_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_maia_common_shares_preserved PASSED
tests/test_ticker_synthesis_workflow.py::test_safety_flags_correct PASSED
tests/test_ticker_synthesis_workflow.py::test_no_recommendation_language PASSED
tests/test_ticker_synthesis_workflow.py::test_required_schema_keys PASSED
tests/test_ticker_synthesis_workflow.py::test_biotech_profile_has_clinical_module PASSED
tests/test_ticker_synthesis_workflow.py::test_evidence_matrix_structure PASSED
tests/test_ticker_synthesis_workflow.py::test_overall_posture_no_recommendation PASSED
tests/test_ticker_synthesis_workflow.py::test_source_boundary_documented PASSED
tests/test_ticker_synthesis_workflow.py::test_no_secrets_in_output PASSED
tests/test_ticker_monitoring_pack.py::test_monitoring_plan_structure PASSED
tests/test_ticker_monitoring_pack.py::test_monitoring_baseline_from_synthesis PASSED
tests/test_ticker_monitoring_pack.py::test_monitoring_categories_present PASSED
tests/test_ticker_market_confirmation.py::test_market_confirmation_structure PASSED
tests/test_ticker_market_confirmation.py::test_reference_price_documented PASSED
tests/test_ticker_market_confirmation.py::test_csv_observation_template_exists PASSED
tests/test_ticker_archive_packet.py::test_archive_manifest_structure PASSED
tests/test_ticker_archive_packet.py::test_artifacts_have_checksums PASSED
tests/test_ticker_archive_packet.py::test_archive_safety_flags PASSED

============================= 25 passed in 0.10s ==============================
```

**All 25 tests passing** ✓

### Test Coverage

- MAIA baseline preservation: 8 tests ✓
- Safety flags: 3 tests ✓
- Recommendation language: 2 tests ✓
- Schema structure: 4 tests ✓
- Evidence matrix: 1 test ✓
- Biotech profile handling: 1 test ✓
- CSV template generation: 1 test ✓
- Archive checksums: 1 test ✓
- Source boundary: 1 test ✓
- Secrets exclusion: 1 test ✓
- Monitoring/archive structure: 2 tests ✓

## Smoke Test Result

**Skipped** - Production dual-channel pilot is active (per CP22D). Smoke test was not run to avoid any risk of triggering alerts.

Per instruction: "Run smoke test only if safe and not alert-triggering. Since production dual-channel pilot is active, skip smoke if there is any chance of sending alerts and explain."

**Explanation:** All scripts enforce `alerts_generated: false`, but as a safety precaution during active production pilot, smoke test was omitted. The 25 automated tests provide comprehensive validation coverage.

## Secret Scan Result

**Scan command:**
```powershell
Get-Content sources\ticker_synthesis_utils.py, scripts\ticker_*.py, schemas\*.json, docs\workflows\*.md, docs\sample_reports\generic_ticker\MAIA\**\*.json |
  Select-String -Pattern 'TELEGRAM_BOT_TOKEN=|TELEGRAM_CHAT_ID=|SMTP_PASSWORD=|...' |
  Measure-Object | Select-Object -ExpandProperty Count
```

**Result:** 0 matches ✓

**Patterns scanned:**
- TELEGRAM_BOT_TOKEN=
- TELEGRAM_CHAT_ID=
- SMTP_PASSWORD=
- SMTP_USERNAME=
- GMAIL_APP_PASSWORD=
- sk-ant-api
- sk-ant-
- ETHERSCAN_API_KEY=
- SEC_API_IO_API_KEY=
- BEGIN PRIVATE KEY
- password=
- token=
- chat_id=
- xoxb- (Slack)
- ghp_ (GitHub)

**No secrets found** ✓

## Commit Hash

*Will be added after successful commit*

## Push Result

*Will be added after successful push*

## Risks/Blockers

### None Identified

All validations passing. Framework skeleton complete and MAIA validation successful.

### Future Implementation Considerations

For the next checkpoint that implements full SEC extraction:

1. **SEC EDGAR API rate limits** - Need to implement respectful scraping with delays
2. **Form 4 XML parsing** - Malformed/non-standard XML from some filers
3. **10-Q/10-K XBRL parsing** - Complex namespace handling, different taxonomy versions
4. **CIK lookup** - Need reliable ticker → CIK mapping (SEC company tickers API)
5. **Error handling** - Graceful degradation when filings unavailable or parsing fails
6. **Clinical data extraction** - Requires parsing free-text MD&A sections or ClinicalTrials.gov integration

## Recommended Next Step

**Three options for PM review:**

### Option A: CP23I - Second Validation Ticker

Run the generic workflow on a second ticker (non-biotech, e.g., small-cap operating company) to validate profile handling and identify additional edge cases.

**Pros:**
- Further validates generic framework
- Tests non-biotech profile handling
- Low risk (still validation mode, no new SEC extraction)

**Cons:**
- Requires manual creation of second ticker baseline data

### Option B: CP24 - Full SEC Extraction Implementation

Implement the full SEC EDGAR extraction pipeline for arbitrary tickers.

**Pros:**
- Unlocks live ticker research capability
- High value deliverable
- Completes the generic workflow vision

**Cons:**
- Substantial engineering effort
- Higher complexity and risk
- Requires thorough testing across multiple tickers

### Option C: CP22E - Production Monitoring

Return to production dual-channel pilot monitoring after next normal Ross run.

**Pros:**
- Validates production alert system stability
- Monitors real user alerts
- Low implementation effort

**Cons:**
- Delays generic workflow completion

**PM Decision Required:** Which checkpoint to pursue next?

## Awaiting PM Approval

CP23C is complete and ready for PM review.

**Questions for PM:**

1. Is the skeleton framework approach acceptable, or should full SEC extraction be implemented before moving forward?
2. Should we validate with a second ticker (non-biotech) before implementing full extraction?
3. Should we prioritize full SEC extraction (CP24) or return to production monitoring (CP22E)?
4. Are there specific ticker types or edge cases that should be addressed in the framework?
5. Should markdown templates be enhanced with Jinja2 before full extraction implementation?

---

**Checkpoint:** CP23C
**Status:** COMPLETE ✓
**Framework:** Skeleton + MAIA validation passing
**Test Results:** 25/25 passing
**Safety:** All constraints enforced
**Baseline:** All MAIA values preserved
**Next:** Awaiting PM direction on Option A/B/C
